Arzneimittelforschung 2007; 57(4): 232-237
DOI: 10.1055/s-0031-1296610
Antibiotics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Bio equivalence Study of Sultamicillin Suspensions

Reinhard Sailer
1  Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany
,
Peter Arnold
1  Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany
,
Aydin Erenmemişoğlu
2  DEKAM-IKU,Good Clinical Practices Center, Erciyes University, Medical School, Kayseri, Turkey
,
Wolfgang Martin
1  Pharmakin GmbH, Gesellschaft für Pharmakokinetik, Ulm, Germany
,
Uygur Tamur
3  DEVA Holding A.Ş, 4. Levent, Istanbul, Turkey
,
Ilker Kanzik
4  IDE Pharmaceutical Consulting, Kavaklidere, Ankara, Turkey
5  Gazi University Faculty of Pharmacy, Department of Pharmacology, Etiler Ankara, Turkey
,
A. Atilla Hincal
4  IDE Pharmaceutical Consulting, Kavaklidere, Ankara, Turkey
6  Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Sihhiye, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

Publication Date:
21 December 2011 (online)

Abstract

Sultamicillin (CAS 76497-13-7) is a prodrug combination of ampicillin (CAS 69-53-4) and sulbactam (CAS 68373-14-8), with the antibiotic ampicillin and the beta-lac-tamase inhibitor sulbactam chemically linked as double ester. The present study was performed to investigate the relative bioavailability and to assess the bioequivalence of two different sultamicillin suspensions (Devasid© 250 mg/5 ml as test preparation and 375 mg/7.5 ml of the originator product as reference preparation). Twenty-four healthy male volunteers received equal doses of the sultamicillin preparations according to an open, randomised, single-dose, two-period cross-over design with a wash-out phase of 7 days.

Blood samples for pharmacokinetic profiling were taken up to 8 h post-dose, and ampicillin and sulbactam plasma concentrations were determined with a validated LC-MS/MS method.

Maximum plasma concentrations (Cmax) of 11,267.4 ng/ml (ampicillin, test), 10,864.4 ng/ml (ampicillin, reference), ng/ml (sulbactam, test and ng/ml (sulbactam, reference) were achieved. Areas under the plasma concentration-time curve (AUC0→∞)of 17,512.9 ng · h/ml (ampicillin, test), 18,388.0 ng · h/ml (ampicillin, reference), 10,971.7 ng · h/ml (sulbactam, test) and 11,181.2 ng · h/ml (sulbactam, reference) were calculated. The median tmax was 0.69 h (ampicillin, test), 0.85 h (ampicillin, reference), 0.72 h (sulbactam, Devasid©) and 0.83 h (sulbactam, reference). Plasma elimination half-lives (t1/2) of 1.04 h (ampicillin, test), 1.03 h (ampicillin, reference), 1.26 h (sulbactam, Devasid©) and 1.00 h (sulbactam, reference) were determined. Both primary target parameters AUC0→∞ and Cmax of ampicillin and sulbactam were tested parametrically by analysis of variance (ANOVA) and the 90% confidence intervals were between 84.58%-117.80% (AUC0→∞ ampicillin), 92.37%-l 19.93% (Cmax, ampicillin), 85.81 %-l 20.50% (AUC0→∞, sulbactam) and 88.41 %-117.57% (Cmax, sulbactam). Bioequivalence between test and reference preparation was demonstrated since for both parameters AUC and Cmax the 90% confidence intervals of the T/R-ra-tios of logarithmically transformed data were in the generally accepted range of 80%-125%.